MiRNA-30a functions as a tumor suppressor by downregulating cyclin E2 expression in castration-resistant prostate cancer

Molecular Medicine Reports

Volumn 14, Issue 3, 2016, Pages 2077-2084

  Zhang, Lei ^a,b   Zhang, Xiao Wen ^a,b   Liu, Chun Hui ^a,b   Lu, Kai ^a,b   Huang, Ye Qing ^a,b   Wang, Yi Duo ^a,b   Xing, Li ^a   Zhang, Li Jie ^a   Liu, Ning ^a   Jiang, Hua ^a   Sun, Chao ^a   Yang, Yu ^a   Chen, Shu Qiu ^a   Chen, Ming ^a,b   Xu, Bin ^a,b  

^a SOUTHEAST UNIVERSITY   (China)

^b State Key Laboratory of Pharmaceutical Biotechnology   (China)

Author keywords

Androgen dependent prostate cancer; Castration resistant prostate cancer; CCNE2; Metastasis; MiR 30a; Proliferation

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN E2; CYCLINE; MICRORNA; MICRORNA 30A; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CCNE2 PROTEIN, HUMAN; MIRN30 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ARTICLE; CANCER PATIENT; CANCER TISSUE; CARCINOGENESIS; CARCINOGENICITY; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CLINICAL OUTCOME; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MALE; MOUSE; MTT ASSAY; NONHUMAN; PROSTATE CANCER CELL LINE; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; APOPTOSIS; BINDING SITE; BIOLOGY; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; XENOGRAFT;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BINDING SITES; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COMPUTATIONAL BIOLOGY; CYCLINS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HETEROGRAFTS; HUMANS; MALE; MICE; MICRORNAS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RNA INTERFERENCE; TUMOR BURDEN;

EID: 84989189582     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5469     Document Type: Article

References (27)

1. Siegel R, Ma J, Zhou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014
2. Feldman BJ and Feldman D: The development of androgen independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001
3. Lai EC: MicroRNAs are complementary to 3'UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30: 363-364, 2002
4. Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med 60: 167-179, 2009
5. Zhang L, Xul B, Chen S, Lu K, Liu C, Wang Y, Zhao Y, Zhang X, Liu D and Chen M: The complex roles of microRNAS in the metastasis of renal cell carcinoma. J Nanosci Nanotechnol 13: 3195-3203, 2013
6. Coppola V, De Maria R and Bonci D: MicroRNAs and prostate cancer. Endocr Relat Cancer 17: F1-F17, 2010
7. Liu D, Tao T, Xu B, Chen S, Liu C, Zhang L, Lu K, Huang Y, Jiang L, Zhang X, et al: MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6). Biochem Biophys Res Commun 445: 151-156, 2014
8. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135, 2007
9. National Research Council: Guide for the care and use of laboratory animals. 7th edition. National Academy Press, Washington DC, 1996
10. Xu B, Wang N, Wang X, Tong N, Shao N, Tao J, Li P, Niu X, Feng N, Zhang L, et al: MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 72: 1171-1178, 2012
11. Ozen M, Creighton CJ, Ozdemir M and Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793, 2008
12. Huang QB, Ma X, Zhang X, Liu SW, Ai Q, Shi TP, Zhang Y, Gao Y, Fan Y and Ni D, et al: Down-Regulated miR-30a in clear cell renal cell carcinoma correlated with tumor hematogenous metastasis by targeting angiogenesis-specific DLL4. PLoS One 8: e67294, 2013
13. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M and Allgayer H: MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 130: 2044-2053, 2012
14. Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J, Cheng L, Fan Z, Yuan B, Tian P, et al: MiR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. Biochem Biophys Res Commun 445: 314-319, 2014
15. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 33: 732-739, 2012
16. Jia Z, Wang K, Wang G, Zhang A and Pu P: MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth by targeting SEPT7. PLoS One 8: e55008, 2013
17. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, deVere White RW and Kung HJ: MiR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 33: 2495-2503, 2014
18. Caldon CE and Musgrove EA: Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div 5: 2, 2010
19. Hwang HC and Clurman BE: Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786, 2005
20. Gudas JM, Payton M, Thukral S, Chen E, Bass M, Robinson MO and Coats S: Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol 19: 612-622, 1999
21. Caldon CE, Sergio CM, Burgess A, Deans AJ, Sutherland RL and Musgrove EA: Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle 12: 606-617, 2013
22. Payton M, Scully S, Chung G and Coats S: Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors. Oncogene 21: 8529-8534, 2002
23. Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, et al: Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 11: 1488-1499, 2012
24. Sieuwerts AM, Look MP, Meijer-Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, et al: Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12: 3319-3328, 2006
25. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406, 2005
26. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799, 2004
27. Wu Z, Cho H, Hampton GM and Theodorescu D: Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia 11: 66-76, 2009